Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F23%3A00574516" target="_blank" >RIV/68081707:_____/23:00574516 - isvavai.cz</a>
Result on the web
<a href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00586" target="_blank" >https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00586</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1021/acs.jmedchem.3c00586" target="_blank" >10.1021/acs.jmedchem.3c00586</a>
Alternative languages
Result language
angličtina
Original language name
Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells
Original language description
Herein, we report a series of new octahedral iridium(III)complexes Ir1-Ir9 of the type [Ir(N<^>N<^>N)(C<^>N)Cl]PF6 (N<^>N<^>N = 4 & PRIME,-(p-tolyl)-2,2 & PRIME,:6 & PRIME,,2 & DPRIME,-terpyridine,C<^>N = deprotonated 2-arylbenzimidazole backbone) to introduce newmetal-based compounds for effective inhibition of metastatic processesin triple-negative breast cancer (TNBC). The results show that thestructural modifications within the C<^>N scaffold strongly impact theantimetastatic properties of these complexes in TNBC cells. Furthermore,testing the antimetastatic effects of the investigated Ir complexesrevealed that the highest antimetastatic activity in TNBC cells isexhibited by complex Ir1. This result was in contrastto the effects of the clinically used drug doxorubicin used in conventionalchemotherapy of TNBC, which conversely promoted metastatic propertiesof TNBC cells. Thus, the latter result suggests that doxorubicin chemotherapymay increase the risk of metastasis of breast cancer cells, so thesearch for new drugs to treat breast cancer that would show betterantitumor effects than doxorubicin is justified.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10402 - Inorganic and nuclear chemistry
Result continuities
Project
<a href="/en/project/GA23-06307S" target="_blank" >GA23-06307S: Metal-based compounds as candidates for antimetastatic chemotherapy</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Medicinal Chemistry
ISSN
0022-2623
e-ISSN
1520-4804
Volume of the periodical
66
Issue of the periodical within the volume
14
Country of publishing house
US - UNITED STATES
Number of pages
18
Pages from-to
9766-9783
UT code for WoS article
001023572900001
EID of the result in the Scopus database
2-s2.0-85164689399